(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 15.08% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.15%.
Supernus Pharmaceuticals's revenue in 2026 is $776,833,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $51,280,415,092, with the lowest SUPN revenue forecast at $48,858,997,932, and the highest SUPN revenue forecast at $53,068,038,499. On average, 8 Wall Street analysts forecast SUPN's revenue for 2027 to be $60,129,150,956, with the lowest SUPN revenue forecast at $56,671,144,379, and the highest SUPN revenue forecast at $63,147,216,448.
In 2028, SUPN is forecast to generate $68,660,989,943 in revenue, with the lowest revenue forecast at $63,379,375,332 and the highest revenue forecast at $73,652,405,949.